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Abstract
Background: TGFβ has pleiotropic effects that range from regulation of proliferation and apoptosis to
morphological changes and epithelial-mesenchymal transition (EMT). Some evidence suggests that these effects
may be interconnected. We have recently reported that P53, P21Cip1 and pRB, three critical regulators of the G1/
S transition are variably involved in TGFβ-induced cell cycle arrest in hepatocytes. As these proteins are also
involved in the regulation of apoptosis in many circumstances, we investigated their contribution to other relevant
TGFβ-induced effects, namely apoptosis and EMT, and examined how the various processes were interrelated.
Methods: Primary mouse hepatocytes deficient in p53, p21 and/or Rb, singly or in combination were treated with
TGFβ for 24 to 96 hours. Apoptosis was quantified according to morphology and by immunostaining for cleaved-
capsase 3. Epithelial and mesenchymal marker expression was studied using immunocytochemistry and real time
PCR.
Results: We found that TGFβ similarly induced morphological changes regardless of genotype and independently
of proliferation index or sensitivity to inhibition of proliferation by TGFβ. Morphological changes were
accompanied by decrease in E-cadherin and increased Snail expression but the mesenchymal markers (N-
cadherin, SMAα and Vimentin) studied remained unchanged. TGFβ induced high levels of apoptosis in p53-/-, Rb-
/-, p21cip1-/- and control hepatocytes although with slight differences in kinetics. This was unrelated to
proliferation or changes in morphology and loss of cell-cell adhesion. However, hepatocytes deficient in both p53
and p21cip1were less sensitive to TGFβ-induced apoptosis.
Conclusion: Although p53, p21Cip1 and pRb are well known regulators of both proliferation and apoptosis in
response to a multitude of stresses, we conclude that they are critical for TGFβ-driven inhibition of hepatocytes
proliferation, but only slightly modulate TGFβ-induced apoptosis. This effect may depend on other parameters
such as proliferation and the presence of other regulatory proteins as suggested by the consequences of p53,
p21Cip1 double deficiency. Similarly, p53, p21Cip1 and pRB deficiency had no effect on the morphological changes
and loss of cell adhesion which is thought to be critical for metastasis. This indicates that possible association of
these genes with metastasis potential would be unlikely to involve TGFβ-induced EMT.
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TGFβ is known to have pleiotropic effects which differ
according to cell state and differentiation (reviewed in ref-
erence [1]). This includes regulation of proliferation and
apoptosis, and stimulation of epithelial-mesenchymal
transition (EMT) which together are critical for the devel-
opment of invasive and metastasis potential.
In the liver TGFβ is released in many settings to act as a
critical mediator of responses to injury [2]. It controls the
proliferation of hepatocytes [3], induces hepatocytes
apoptosis [4] and activates EMT [5-8] which, in certain
contexts can actually protect hepatocytes from TGFβ-
induced apoptosis [9].
In hepatocellular carcinoma (HCC), there is often produc-
tion of TGFβ from both malignant hepatocytes and the
non-parenchymal cells [10,11]. However, evidence sug-
gests that HCC have acquired a resistance to TGFβ inhibi-
tion of proliferation through mechanisms that include
decreased TGFβ-receptor II expression [12] or induction
of the inhibitory SMAD7 in advanced HCC [12,13]. In
HCC of different aetiologies, particularly in livers with
chronic viral hepatitis B or hepatitis C infection, P53,
P21Cip1 and pRb function are altered [14-21]. We have
recently reported that deficiency in these proteins signifi-
cantly affects hepatocyte responses to TGFβ-induced inhi-
bition of proliferation, and may therefore contribute to
resistance to TGFβ [22]. As these proteins are also key reg-
ulators of hepatocyte apoptosis [23] and given the associ-
ation of p53 with metastasis potential [24], we
determined whether deficiency in these genes also altered
TGFβ effects on morphology, EMT and apoptosis, and
investigated the possible relationships between those
changes.
Methods
Hepatocyte culture
Mouse primary hepatocytes (male, 6–12 weeks old), were
isolated by liver perfusion of Rb-floxed mice
(homozygous for exon 19 of Rb flanked by LoxP
sequences)[25]p53-/- [26] and p21Cip1-null mice [18]
using a standard two-step retrograde procedure [27].
Hepatocytes were purified using Percoll gradient [28] and
cultured in supplemented serum-free medium selecting
against survival of non-parenchymal cells. [29,30]. Rb-
floxed hepatocytes were infected at the time of plating
with either a replication-deficient adenovirus expressing
Cre-recombinase (Ad-Cre) or with the control adenovirus
(Ad-Dl70) using a multiplicity of infection of 10 [23].
This gave rise to isogenic hepatocytes either homozygous
for the floxed-Rb allele (phenotypically wild-type) or
homozygous for deletion of exon 19 of Rb (Rb-null).
Where indicated, hepatocytes were treated daily with
160pM of TGF-β 1 (TGFβ) for the indicated time starting
from 24 hours of culture.
All animals used in this study received humane care. The
study protocols are in compliance with the UK Home
Office regulation and the local institutional policies.
Quantification of apoptosis
Cells were prepared using Feulgen stain and light green
counterstain [31,32]. Briefly, cells were fixed in Boum's
fixative, treated with 5M HCl for 45 minutes then stained
with Schiff reagent. Apoptosis was quantified according
the morphological characteristics of the cells as previously
described [33]. Normal hepatocytes are flat, with big pale
pink nuclei and green cytoplasm while necrotic hepato-
cytes have shrunken and distorted nuclei darker pink and
no condensation of the chromatin (see additional file 1).
Apoptotic cells have condensed, uniformly refractile chro-
matin with retracted condensed cytoplasm (dark green)
often with blebbing. Typically apoptotic bodies are best
seen at a different plane of focus (above) normal cells. For
each time point of each experiment 500 hepatocytes were
counted from 2 independent cultures allowing us to plot
a percentage of apoptotic cells +/- SD. Each experiment
was repeated at least 3 times with similar results.
Statistical analyses were performed using Minitab 13.0.
The proportion of apoptotic cells was arcsine trans-
formed, and differences between means were evaluated
with Analysis of Variance (ANOVA). Differences were
taken to be significant when p < 0.05. Satisfactory homo-
geneity of variances was determined with Bartlett's test.
Where a significant difference between means was identi-
fied with ANOVA, pairwise comparisons were performed
using Bonferroni tests for multiple comparisons.
In addition to morphological assessment, activation of
apoptosis was confirmed biochemically by quantification
of cleaved-caspase 3. Briefly, hepatocytes in culture for 72
and 96 hours, treated or not with TGFβ, were fixed in ace-
tone/methanol. Cleaved-caspase 3 was labelled using a
rabbit polyclonal antibody (9661S, New England Biolabs,
UK) (1/100 overnight) and red-fluorescent secondary
antibody (Alexa555 goat antirabbit, molecular probes,
UK).
Immunohistochemistry
Control (wt) and Rb -/- hepatocytes in culture for 24 hours
on Permanox 2-well chamberslides (LabTech, UK) were
treated daily or not with TGFβ(160pM of TGF-β1). 72
hours after treatment (96 hours after plating) the hepato-
cytes were fixed in Acetone/Methanol (50/50 V/V). After
Avidin/Biotin block (Vector, UK), the slides were incu-
bated with a rabbit polyclonal anti E-cadherin antibody
(clone NCH38, DAKO UK), rabbit monoclonal anti CK18Page 2 of 11
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SMAα (clone 1A4, Sigma UK) or rabbit polyclonal anti N-
cadherin (AbCam, UK), followed by the appropriate
biotinylated secondary antibody (Dako, UK) and revealed
using ready-to-use peroxidase stain (Vector, UK) and
counterstained with haematoxylin.
Real time RT-PCR
RNA was extracted using Qiagen RNeasy mini kit accord-
ing to manufacturers' instructions. The concentration and
purity of RNA was determined using a NanoDrop® ND-
1000 spectrophotometer (NanoDrop Technologies DE,
USA). Total RNA (up to 1 μg) was reverse transcribed
using Superscript II reverse transcriptase (Invitrogen, UK)
in a reaction mix consisting of: 4 μl of 5× buffer, 2 μl DTT
(0.1 M), 0.5 μl dNTPs (10 mM), 2 μg of random hexam-
ers, 0.5 μl (100 U) Superscript II and 0.5 μl (20 U) RNAse
inhibitor (all Invitrogen, UK). The resulting cDNA was
diluted 1:100 ready for PCR.
Expression of both E-cadherin and Snail was determined
using SYBR green master mix (Invitrogen, UK) and the fol-
lowing primers: E-Cadherin: Forward primer ACT GTG
AAG GGA CGG TCA AC; Reverse primer GGA GCA GCA
GGA TCA GAA TC. Snail: Forward primer CCA CTG CAA
CCG TGC TTT T; Reverse primer TCT TCA CAT CCG AGT
GGG TTT. Pre-designed 18S primer/probe (Applied Bio-
systems, UK) was run as an internal control using a Taq-
Man master mix (Invitrogen, UK). Each system was run
under standard conditions on an ABI 7500 detection sys-
tem
Results
TGFβ induces a high level of apoptosis in hepatocytes 
deficient in p53, p21 and/or Rb, but the sensitivity is 
genotype-dependent
TGFβ can induce apoptosis in certain cell-types, including
hepatocytes [4,34,35]. Given the role of P53 and pRb,
respectively as a positive and a negative regulator of apop-
tosis induced by a variety of stimuli [36,37], we investi-
gated whether the absence of either gene alters the
susceptibility of hepatocytes to TGFβ-induced apoptosis.
We found that hepatocytes of all tested genotypes
undergo apoptosis after treatment with TGFβ. Interest-
ingly, apoptotic cells were observed earlier in p53-/-, Rb-/-
and double null cultures (p53Rb-/-) compared with wild-
type (4.41; 4.26 and 2.71% versus 0.52% in untreated
wild type control 48 hours after treatment) (figure 1A)
indicating that the loss of Rb or p53 sensitises hepatocytes
to TGFβ-induced death.
We then studied the effect of p21Cip1 deficiency (figure
1B). The absence of functional P21Cip1 had no effect on
TGFβ-induced apoptosis in hepatocytes with functional
P53 (control and Rb-/-) (figure 1B). By contrast, regardless
of Rb status, deficiency in both P53 and P21Cip1 decreased
the sensitivity to TGFβ (decreased apoptosis both in dou-
ble p53-/-p21Cip1-/- and triple-nulls p53-/-Rb-/-p21Cip1-/-)
(figure 1C). These differences in apoptosis levels were
confirmed by labelling the cells with an antibody specific
for cleaved caspase 3 (ASP175) (figure 2). The results were
concordant with the morphology data: after 48 hours of
treatment with TGFβ (72 hours in culture) control, p53
p21cip1-/- and TRPL hepatocytes had similar low levels of
cleaved-caspase 3 (figure 2A). Hepatocytes of all other
genotypes exhibited higher levels of cleaved-caspase 3,
with the highest level observed in Rb-/- cells. This is in
accordance with the kinetics of appearance of cells with
apoptotic morphology (figure 1). After 72 hours of treat-
ment (96 hours in culture) the levels of cleaved-capsase 3
increased in hepatocytes of all genotypes but control,
p53p21-/- and TRPL showed the lowest levels of cleaved-
caspase 3 positivity.
We have previously reported that p53, p21Cip1 and Rb defi-
ciencies lead to increased proliferation albeit of different
magnitude depending on the genotype [23]. More
recently, we have shown that these genes are also involved
in the regulation of TGFβ-induced cell cycle arrest, but
again to various degrees [22]. It has been suggested that
increased cell cycle activity can lower the apoptotic thresh-
old which would explain the early onset of apoptosis in
p53-/- and Rb-/-. The current observation that apoptosis
starts when the first untreated cells enter mitosis (90 to 96
hours after plating in wild-type, and around 72 hours in
p53-/- and Rb-/- cells) might indicate that TGFβ induces a
coordinated regulation of growth and apoptosis. However
the level of proliferation and apoptosis were found to be
unrelated in these cells (additional file 2A). In fact, regard-
less of p53 and Rb genotypes, hepatocytes deficient in
p21Cip1 always proliferate more but showed less apoptosis
after TGFβ-treatment than their "wild type for
p21Cip1"counterpart (additional file 2B follow blue
arrows). By contrast deletion of Rb always increased pro-
liferation and apoptosis after TGFβ, regardless of the other
genes' status (additional file 2B, follow purple arrows).
TGFβ induces morphological changes regardless of 
genotype
TGFβ stimulates production of extracellular matrix (ECM)
proteins and their integrin receptors [38], thus affecting
cytoskeletal structure, cell shape, and cell spreading,
which in turn regulate gene expression and cell growth
[39,40]. We observed that TGFβ-treated hepatocytes
exhibited dramatic changes in cell shape and spreading.
Untreated hepatocytes cultured on plastic coated with
fibronectin spread to form a monolayer of cobblestone
epithelioid cells. By contrast, TGFβ-treated cells became
elongated with reduced cytoplasm and assumed a fibrob-Page 3 of 11
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Effect of p53, p21Cip1 and Rb deficiency on hepatocyte sensitivity to TGFβ-induced apoptosisFigure 1
Effect of p53, p21Cip1 and Rb deficiency on hepatocyte sensitivity to TGFβ-induced apoptosis. Where appropriate 
cells were treated with TGFβ from 24 hours in culture. For apoptosis curves in A, B & C, each time point is the average per-
centage of apoptotic cells +/- SDV obtained from two cultures where 500 cells were counted. The experiment was repeated 3 
times with similar results. Control cells are shown in all graphs; in blue control cells treated with TGFβ. Untreated controls are 
shown with open symbols. The tables show the p values of statistical analysis for pairwise comparison of apoptosis in the gen-
otype of interest (see text and methods). A: p53 &Rb deficiency increase sensitivity to apoptosis. The curves show the % of 
apoptotic cells in control (▲,); p53-/- (,■); Rb-/- (❍,●); and p53-/- Rb-/-(?, ) cells treated (plain) or not (open) with 
TGFβ. B: p21Cip1-deficiency has no effect on Rb -/- cells. The curve shows the percentage of apoptosis in cells of indicated gen-
otypes either wild type (black/blue) or deleted for p21Cip1 (red) treated or not with TGFβ. C: Cells deficient in both p53 and 
p21Cip1 are less sensitive to TGFβ-induced apoptosis. Compare black symbols (single nulls for p53 or p21Cip1) with red symbols 
(deficient in both p53 and p21Cip1).
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BMC Cancer 2008, 8:191 http://www.biomedcentral.com/1471-2407/8/191last-like morphology (figure 3). These changes occurred
regardless of genotype and are similar to those described
as epithelial to mesenchymal transition (EMT). We there-
fore investigated the expression of various proteins that
characterise EMT [41].
Caspase 3 cleavage in hepatocytes of different genotypesFigure 2
Caspase 3 cleavage in hepatocytes of different genotypes. Cleaved-caspase 3 was labelled using red immunofluores-
cence and the proportion of positive cells quantified by counting 3 × 20 fields of view per genotype. B: The figure shows repre-
sentative photos of (a, b) untreated hepatocytes 72 hours after plating (here Rb-/-); (c, d) hepatocytes in culture for 72 hours 
treated with TGFβ for 48 hours (p 53-/- & control); (e) untreated hepatocytes 96 hours after plating (p21cip1-/-); (f, g, h) hepa-
tocytes in culture for 96 hours treated with TGFβ for 72 hours (p53 p21cip1-/-, control &p21cip1-/-).Page 5 of 11
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EMT is characterised by changes in expression of various
proteins, in which downregulation of E-cadherin and con-
comitant expression of N-cadherin represents defining
events ([42] and therein). We analysed the expression of
these proteins, together with the expression of vimentin
and alpha-smooth muscle actin (SMAα), also expected to
increase during EMT (figure 4A) and cytokeratin 18
(CK18), an epitheial hepatocyte marker. As expected, pri-
mary hepatocytes expressed E-cadherin and CK18 but not
vimentin, N-cadherin or SMAα. After TGFβ-treatment, E-
cadherin staining was negative in all genotypes. By con-
trast there were no changes in expression of N-cadherin,
SMAα and vimentin (all negative) or cytokeratin 18 (pos-
itive). To confirm these data, we studied E-cadherin, Snail
(a key regulator of E-cadherin expression during EMT)
and N-cadherin gene expression. Using real time PCR we
found that E-cadherin expression decreased with TGFβ-
treatment while Snail expression increased in cells of all
genotypes (figure 4B). N-cadherin expression was barely
detectable and no increase in expression was observed
after TGFβ-treatment (data not shown).
Discussion
TGFβ has pleiotropic effects ranging from regulation of
proliferation and apoptosis to morphological changes
and mesenchymal transition (EMT). Our evidence sug-
gests that these effects may be interconnected: for exam-
ple, TGFβ stimulates the production of extracellular
matrix proteins and their receptors [38], affecting
cytoskeletal structure, cell shape, and cell spreading,
which in turn regulates gene expression and cell prolifera-
tion [39,43].
We have recently reported that P53, P21Cip1 and pRB,
three critical regulators of the G1/S transition are variably
involved in TGFβ-induced cell cycle arrest in hepatocytes
[22]. As these proteins are also involved in the regulation
of apoptosis in many circumstances [36,37], we investi-
gated their contribution to other TGFβ-induced effects,
namely apoptosis and EMT, and examined how these dif-
ferent processes were interrelated.
One of TGFβ properties is to induce morphological
changes associated with epithelial to mesenchymal transi-
tion (EMT), which is characterised by downregulation of
epithelial markers concomitant with upregulation of mes-
enchymal markers [44-46]. Mouse primary hepatocytes of
all genotypes expressed high levels of E-cadherin and
CK18, two epithelial markers. After treatment with TGFβ,
the morphological changes observed were consistent with
that seen during EMT: E-cadherin expression decreased
sharply while snail expression increased. However, mesen-
chymal markers expression was not significantly increased
(N-cadherin, vimentin, SMAα) and CK18 remained
unchanged. Therefore the morphological changes were
only associated with changes in E-cadherin expression,
and this is most probably driven by snail [47] and reflect
loss of epithelial differentiation rather than mesenchymal
transition. Why mesenchymal markers were not expressed
is unclear, but longer exposure (4 to 6 days) to several sig-
nals may be required for completion of EMT [48]. In any
case, this occurred for all genotypes suggesting that P53,
P21Cip1 and pRB are not involved in these changes. Never-
theless, morphological changes and proliferation have
been shown to be correlated. For example, in rat hepato-
cytes, morphological changes induced by TGFβ-treatment
govern proliferation through alteration of p27KIP1 and
p21Cip1 expression [49]. In our cells, TGFβ-treatment did
TGFβ induces morphological changes regardless of genotypeFigure 3
TGFβ induces morphological changes regardless of 
genotype. The figure shows representative photos of con-
trol, Rb-/-, p53-/- and p21Cip1-/- cells 72 hours after plating, 
TGFβ-treated or not for 48 hours. The cells were cultured in 
the presence of BrdU to assess proliferation indexes for 
another study [23]. The dark nuclei represent immunoposi-
tivity for BrdU. Negative nuclei are paler.Page 6 of 11
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TGFβ decreases E-cadherin expressionFigure 4
TGFβ decreases E-cadherin expression. A: The figure shows representative photos of control, Rb-/-, p53-/- and p21Cip1-/
- cells 96 hours after plating, TGFβ-treated or not for 72 hours labelled for E-cadherin, N-cadherin, SMAα, vimentin and CK18. 
Positive controls: E-cadherin: membrane staining of hepatocytes; N-cadherin: mouse primary hepatic stellate cells; SMAα: mouse 
primary hepatic stellate cell; cytokeratin 18: staining of hepatocytes but not sinusoidal cells; vimentin: intense staining of sinusoi-
dal cells but not hepatocytes. B: E-cadherin and snail expression corrected for 18S amplification in hepatocytes treated or not 
with TGFβ for 72 hours. Repeat real time RT-PCR with independent samples showed similar results except for snail expres-
sion in p21-/- which was already high and did not further increase after TGFβ-treatment.
BMC Cancer 2008, 8:191 http://www.biomedcentral.com/1471-2407/8/191not upregulate p27KIP1 [22]. The morphological altera-
tions also occurred similarly without p21Cip1, suggesting
that these cyclin-dependent kinases (CDKI) are not
required for this TGFβ-effect in primary adult mouse
hepatocytes. Furthermore, the morphological changes
occurred irrespective of genotypes which we have previ-
ously reported have differing proliferation index [23] and
responses to inhibition of proliferation by TGFβ [22]. This
demonstrates that TGFβ-signalling to morphological
changes is different to its growth inhibitory signalling in
primary mouse hepatocytes. A similar observation has
recently been reported for human keratinocytes [50].
TGFβ is well described as a trigger for apoptosis in hepa-
tocytes [35] and high level of apoptosis was observed
regardless of genotype studied. Apoptosis appeared some-
what later than in other published studies where high lev-
els are usually reported after 48 hours of TGFβ; the fact
that primary hepatocytes in our system are almost syn-
chronous in terms of entry from quiescence to cell cycle
on plating [22,23,32] may be a factor and supports the
hypothesised influence of cell cycle stage on TGFβ-
induced apoptosis. In our study, apoptosis triggered by
TGFβ occurred earlier in p53 and Rb-deficient cells than in
control cells, showing an increased sensitivity. It has been
suggested that increased cell cycle activity may lower the
threshold for apoptosis. More specifically, the abundance
of pRb and its level of phosphorylation have been shown
to correlate with the threshold for TGFβ-induced apopto-
sis in hepatocytes [51]. In that study, Fan et al reported an
enrichment of the G2/M population after TGFβ-treatment
and proposed that TGFβ-induced apoptosis occurred in
G1 or S phase [51]. In our system, using near synchronous
adult primary hepatocytes, TGFβ-treatment triggers a
strong and sustained G1-arrest in control cells [22] (less
than 1% cells entering S phase) supporting the hypothesis
that TGFβ-induced apoptosis occurs in G1. However, the
earlier onset of apoptosis in p53 and Rb-null cells corre-
lates with the peak of S phase and the appearance of the
first mitosis suggesting that in cells escaping TGFβ-
induced cell cycle arrest, another exit to apoptosis may
exist in S phase and G2/M. Although this could contribute
to the higher level of apoptosis in Rb-/- and p53-/- hepato-
cytes [23] it is clearly not the case in p21-/- hepatocytes: we
have previously reported that p21cip1 -/- hepatocytes prolif-
erate more and enter S phase earlier than p53 or Rb-/- cells
[23] and that a substantial proportion of p21cip1-/- cells
treated with TGFβ are able to enter S phase (10.3% +/- 3.3
in p21-/- versus 0.70% +/- 0.42 in control hepatocytes;
([22] and additional file 2). Despite this sustained prolif-
eration in p21cip1-/- cells, apoptosis was of similar level to
that of control cells. Similarly, p21cip1Rb-/- cells proliferate
more than Rb-/- cells after TGFβ-treatment (21.1% +/-
0.26 versus 9.05% +/- 3.17 respectively, additional file 2),
yet apoptosis was not significantly different in those cells.
This may suggest that the presence of p21cip1, and more
particularly expression of cytoplasmic P21Cip1after TGFβ-
treatment [22] which has been associated with apoptosis
[52], sensitises hepatocytes to TGFβ-induced apoptosis
independently to the proliferation index.
In fact, comparison of all genotypes revealed no simple
relationship between the level of proliferation and the
amount of apoptosis (additional file 2). This therefore
suggests that other parameters are important and that
higher proliferation itself can not predict cells' sensitivity
to TGFβ.
Interestingly, apoptosis induced by TGFβ in p53-null cells
was at least partially, dependent on P21Cip1 (regardless of
Rb genotype) as double deficiency in p53 and p21cip1
decreases the level of apoptosis. This effect is specific to
TGFβ as it is not observed when apoptosis is induced by
other means such as UV-induced DNA-damage (data not
shown).
Various recent reports have shown an association between
resistance to apoptosis and EMT in hepatocytes [8,9,53].
In one study, TGFβ treatment of a subpopulation of fetal
rat hepatocytes resulted in EMT which was associated with
resistance to apoptosis. By contrast, adult rat hepatocytes
which did not undergo EMT, died by apoptosis [54]. In
our system, the morphological changes and loss of cell
adhesion may be insufficient to provide resistance, or the
pathway may be different in adult primary mouse hepato-
cytes. This is suggested by the recent study from Ju et al.
[55] that showed that Smad2 deficiency leads to EMT but
does not affect apoptosis in adult primary hepatocytes.
Conclusion
During carcinogenesis, growth inhibitory responses to
TGFβ are often lost, and insufficient apoptosis has been
associated with the development of hepatocellular carci-
noma [56]. P53, P21Cip1 and pRb are well known regula-
tors of both proliferation and apoptosis in response to a
multitude of stresses. In a previous study, we found that
p53, p21cip1and Rb deficiencies decreased the sensitivity of
primary hepatocytes to TGFβ-driven cell cycle arrest. Rb
deficiency had the strongest effect which was independent
of the presence of p53 and p21cip1 [22]. Our present results
reveal a more subtle involvement of theses genes in the
regulation of TGFβ-induced apoptosis. Although differ-
ences in the onset of apoptosis were observed in the dif-
ferent genotypes, all but p53 p21cip1 double null remained
very sensitive to apoptosis induced by TGFβ. We therefore
propose that p53 and Rb have only slight modulatory
effect on TGFβ-induced apoptosis and that other parame-
ters including proliferation index, presence of P21CIP1 and
double deficiency in p53 and p21cip1 are likely to be more
important.Page 8 of 11
(page number not for citation purposes)
BMC Cancer 2008, 8:191 http://www.biomedcentral.com/1471-2407/8/191EMT is thought to be critical for metastasis. Increased snail
expression and decreased E-cadherin, associated with
changes of morphology occurred irrespective of p53,
p21Cip1 and pRb genotypes without mesenchymal transi-
tion, suggesting that the association of p53 deficiency with
metastasis in the liver [24] for example does not correlate
with a change in the ability of hepatocytes to undergo loss
of cell adhesion induced by TGFβ.
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Representative photos of primary hepatocytes necrosis and apoptosis. 
Our method of quantifying apoptosis and necrosis is based on the morpho-
logical characteristics of the cells. Those have been well described, by Kerr 
JF, Wyllie AH, and Currie AR who first described apoptosis in 1972 
(Apoptosis: a basic biological phenomenon with wide-ranging implica-
tions in tissue kinetics.Br J Cancer 1972; 26: 239–257). Enclosed are 
photos of normal, apoptotic and necrotic hepatocytes, showing how easy 
these different cells can be recognised after Feulgen staining and light 
green counterstain. The colours on the photos are real and have not been 
modified; the cytoplasm is green and the chromatin pink. Normal hepato-
cytes are flat, with big pale pink nuclei and green cytoplasm. Necrotic 
hepatocytes have shrunken and distorted nuclei darker pink and no con-
densation of the chromatin. Apoptotic cells have condensed, uniformly 
refractile chromatin with retracted condensed cytoplasm (dark green) 
often with blebbing. Typically apoptotic bodies are best seen at a different 
plane of focus (above) normal cells. 1 & 2: photos of the same field show-
ing some apoptotic cells in a different plan of focus compared with normal 
and necrotic cells. 3: In this photo, showing apoptotic, necrotic and nor-
mal hepatocytes, the apoptotic cells in the black rectangles have been taken 
on a different plan of focus to show the apoptotic bodies. Note that necrotic 
nuclei is "detaching" from cytoplasm area that is not condensed, whereas 
apoptotic cells have highly condensed chromatin and cytoplasm.
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[http://www.biomedcentral.com/content/supplementary/1471-
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Proliferation does not dictate the level of apoptosis. A: The graph rep-
resents the index of proliferation versus the percentage of apoptosis in 
TGFβ-treated hepatocytes of indicated genotypes. The percentage of prolif-
eration after TGFβ-treatment was calculated by integration of the number 
of cells incorporating BrDU between 72 and 108 hours after plating (48 
and 84 hours of TGFβ) [22]. Using videomicroscopy, we have observed 
that, in our culture conditions, the apoptotic primary hepatocytes remain 
attached for many days to the plate. The number of apoptotic cells counted 
at a given time is therefore a good estimation of the number of cells under-
going apoptosis until that time. The graph therefore shows the % apoptotic 
cells at 108 hours. A similar analysis was performed with proliferation 
and apoptosis values for 120 hours with similar results. Note the absence 
of relationship between proliferation and apoptosis. B: As above with 
arrows showing the effect of p53 (red), Rb (purple) or p21Cip1 (blue) 
deficiencies on both apoptosis levels and proliferation for the various gen-
otypes.
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